Opdualag™ (nivolumab/relatlimab-rmbw) – New drug approval
March 18, 2022 - Bristol Myers Squibb announced the FDA approval of Opdualag (nivolumab/relatlimab-rmbw), for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
Download PDF
